These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33046090)

  • 41. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children.
    Tauber M; Barbeau C; Jouret B; Pienkowski C; Malzac P; Moncla A; Rochiccioli P
    Horm Res; 2000; 53(6):279-87. PubMed ID: 11146368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood.
    Coupaye M; Lorenzini F; Lloret-Linares C; Molinas C; Pinto G; Diene G; Mimoun E; Demeer G; Labrousse F; Jauregi J; Laurier V; Basdevant A; Polak M; Thuilleaux D; Tauber M; Poitou C
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E328-35. PubMed ID: 23284006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of adiponectin receptor expression with cytokines and insulin sensitivity in growth hormone (GH)-treated children with Prader-Willi syndrome and in non-GH-treated obese children.
    Sohn YB; Kwak MJ; Kim SJ; Park SW; Kim CH; Kim MY; Kwon EK; Paik KH; Jin DK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1371-7. PubMed ID: 20061428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicentric Italian case-control study on 25OH vitamin D levels in children and adolescents with Prader-Willi syndrome.
    Panfili FM; Convertino A; Grugni G; Mazzitelli L; Bocchini S; Crinò A; Campana G; Cappa M; Delvecchio M; Faienza MF; Licenziati MR; Mariani M; Osimani S; Pajno R; Patti G; Rutigliano I; Sacco M; Scarano E; Fintini D;
    J Endocrinol Invest; 2023 Jul; 46(7):1397-1406. PubMed ID: 36708456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
    Fillion M; Deal C; Van Vliet G
    J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index.
    Butler MG; Matthews NA; Patel N; Surampalli A; Gold JA; Khare M; Thompson T; Cassidy SB; Kimonis VE
    Am J Med Genet A; 2019 Sep; 179(9):1826-1835. PubMed ID: 31313492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Somatropin therapy in adults with Prader-Willi syndrome.
    Höybye C; Thorén M
    Treat Endocrinol; 2004; 3(3):153-60. PubMed ID: 16026111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children.
    Bizzarri C; Rigamonti AE; Luce A; Cappa M; Cella SG; Berini J; Sartorio A; Müller EE; Salvatoni A
    Eur J Endocrinol; 2010 Mar; 162(3):499-505. PubMed ID: 20019130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
    Carrel AL; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome.
    Nyunt O; Harris M; Hughes I; Huynh T; Davies PS; Cotterill AM
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1151-8. PubMed ID: 20333875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr; 1999 Feb; 134(2):215-21. PubMed ID: 9931532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome.
    Höybye C; Holland AJ; Driscoll DJ;
    Orphanet J Rare Dis; 2021 Feb; 16(1):69. PubMed ID: 33557878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment.
    de Lind van Wijngaarden RF; Cianflone K; Gao Y; Leunissen RW; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1758-66. PubMed ID: 20173020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-cultural comparisons of obesity and growth in Prader-Willi syndrome.
    Dudley O; McManus B; Vogels A; Whittington J; Muscatelli F
    J Intellect Disabil Res; 2008 May; 52(Pt 5):426-36. PubMed ID: 18298478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EFFECT OF GROWTH HORMONE THERAPY IN CHILDREN WITH PRADER-WILLI SYNDROME - OUR FIRST EXPERIENCES.
    Stipančić G; Požgaj Šepec M; La Grasta Sabolić L
    Acta Clin Croat; 2018 Dec; 57(4):744-755. PubMed ID: 31168212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10.
    Eiholzer U; Meinhardt U; Rousson V; Petrovic N; Schlumpf M; l'Allemand D
    Am J Med Genet A; 2008 Apr; 146A(7):873-80. PubMed ID: 18257095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.